Alemtuzumab induction in simultaneous pancreas and kidney transplantation

Clinical Transplantation

Volumn 27, Issue 5, 2013, Pages 693-700

  Zachariah, Mareena ^a   Gregg, Austin ^b   Schold, Jesse ^c   Magliocca, Joseph ^d   Kayler, Liise K ^e  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Alemtuzumab; Induction; Pancreas transplantation

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; CYCLOSPORIN; DACLIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CONTROLLED STUDY; DELAYED GRAFT FUNCTION; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HOSPITAL READMISSION; HUMAN; KIDNEY ALLOGRAFT; KIDNEY PANCREAS TRANSPLANTATION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SIMULTANEOUS KIDNEY PANCREAS TRANSPLANTATION; T CELL DEPLETION;

ALEMTUZUMAB; INDUCTION; PANCREAS TRANSPLANTATION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HOSPITALIZATION; HUMANS; KIDNEY TRANSPLANTATION; MALE; PANCREAS TRANSPLANTATION; PROGNOSIS; RECEPTORS, INTERLEUKIN-2; REGISTRIES; REMISSION INDUCTION; SURVIVAL RATE; T-LYMPHOCYTES;

EID: 84884984247     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12199     Document Type: Article

References (37)

1. Gruessner AC, Sutherland DE. Pancreas transplant outcomes for United States (US) cases reported to the United Network for Organ Sharing (UNOS) and non-US cases reported to the International Pancreas Transplant Registry (IPTR) as of October, 2000. Clin Transpl 2000: 45.
2. Humar A, Khwaja K, Ramcharan T et al. Chronic rejection: the next major challenge for pancreas transplant recipients. Transplantation 2003: 76: 918.
3. Reddy KS, Stratta RJ, Shokouh-Amiri H et al. Simultaneous kidney-pancreas transplantation without antilymphocyte induction. Transplantation 2000: 69: 49.
4. Gruessner AC, Sutherland DE. Analyses of pancreas transplant outcomes for United States cases reported to the United Network for Organ Sharing (UNOS) and non-US cases reported to the International Pancreas Transplant Registry (IPTR). Clin Transpl 1999: 51.
5. Stratta RJ, Alloway RR, Hodge E, Lo A. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis. Clin Transplant 2002: 16: 60.
6. Hanaway MJ, Woodle ES, Mulgaonkar S et al. Alemtuzumab induction in renal transplantation. New Engl J Med 2011: 364: 1909.
7. Farney AC, Doares W, Rogers J et al. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation. Transplantation 2009: 88: 810.
8. Ciancio G, Burke GW, Gaynor JJ et al. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up. Clin Transplant 2008: 22: 200.
9. Shapiro R, Zeevi A, Basu A et al. Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody. Transplantation 2008: 85: 1125.
10. Kaufman DB, Leventhal JR, Axelrod D, Gallon LG, Parker MA, Stuart FP. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction-long-term results. Am J Transplant 2005: 5: 2539.
11. Watson CJ, Bradley JA, Friend PJ et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation-efficacy and safety at five years. Am J Transplant 2005: 5: 1347.
12. Gruessner AC, Sutherland DE. Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of May 2003. Clin Transpl 2003: 21.
13. Gruessner RW. Antibody induction therapy in pancreas transplantation. Transpl Proc 1998: 30: 1556.
14. Stratta RJ, Alloway RR, Lo A, Hodge E. Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study. Transplantation 2003: 75: 1260.
15. Schulz T, Papapostolou G, Schenker P, Kapischke M. Single-shot antithymocyte globulin (ATG) induction for pancreas/kidney transplantation: ATG-Fresenius versus Thymoglobulin. Transpl Proc 2005: 37: 1301.
16. Kaufman DB, Leventhal JR, Gallon LG, Parker MA. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction - long-term results. Am J Transplant 2006: 6: 331.
17. Muthusamy AS, Vaidya AC, Sinha S, Roy D, Elker DE, Friend PJ. Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation. Am J Transplant 2008: 8: 2126.
18. Waki K, Sugawara Y, Tamura S et al. Simultaneous pancreas-kidney transplantation in the United States: an analysis of the UNOS registry. Clin Transpl 2010: 35.
19. Burke GW 3rd, Kaufman DB, Millis JM et al. Prospective, randomized trial of the effect of antibody induction in simultaneous pancreas and kidney transplantation: three-year results. Transplantation 2004: 77: 1269.
20. Waki K, Terasaki PI, Kadowaki T. Long-term pancreas allograft survival in simultaneous pancreas-kidney transplantation by era: UNOS registry analysis. Diabetes Care 2010: 33: 1789.
21. Reddy KS, Devarapalli Y, Mazur M et al. Alemtuzumab with rapid steroid taper in simultaneous kidney and pancreas transplantation: comparison to induction with antithymocyte globulin. Transpl Proc 2010: 42: 2006.
22. Gruessner RW, Sutherland DE, Parr E, Humar A, Gruessner AC. A prospective, randomized, open-label study of steroid withdrawal in pancreas transplantation-a preliminary report with 6-month follow-up. Transpl Proc 2001: 33: 1663.
23. Cantarovich D, Karam G, Hourmant M et al. Steroid avoidance versus steroid withdrawal after simultaneous pancreas-kidney transplantation. Am J Transplant 2005: 5: 1332.
24. Saudek F, Malaise J, Boucek P, Adamec M. Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in primary SPK transplantation: 3-year results of the Euro-SPK 001 trial. Nephrol Dial Transplant 2005: 20(Suppl 2): ii3ii62.
25. Tanchanco R, Krishnamurthi V, Winans C et al. Beneficial outcomes of a steroid-free regimen with thymoglobulin induction in pancreas-kidney transplantation. Transpl Proc 2008: 40: 1551.
26. Gallon LG, Winoto J, Chhabra D, Parker MA, Leventhal JR, Kaufman DB. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Transplantation 2007: 83: 1324.
27. Farney A, Sundberg A, Moore P et al. A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation. Clin Transplant 2008: 22: 41.
28. Gruessner AC, Sutherland DE. Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of June 2004. Clin Transplant 2005: 19: 433.
29. Clatworthy MR, Sivaprakasam R, Butler AJ, Watson CJ. Subcutaneous administration of alemtuzumab in simultaneous pancreas-kidney transplantation. Transplantation 2007: 84: 1563.
30. Gruessner RW, Kandaswamy R, Humar A, Gruessner AC, Sutherland DE. Calcineurin inhibitor- and steroid-free immunosuppression in pancreas-kidney and solitary pancreas transplantation. Transplantation 2005: 79: 1184.
31. Gruessner AC, Sutherland DE. Pancreas transplant outcomes for United States (US) cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR). Clin Transpl 2008: 45.
32. Cohen DJ, St Martin L, Christensen LL, Bloom RD, Sung RS. Kidney and pancreas transplantation in the United States, 1995-2004. Am J Transplant 2006: 2: 1153.
33. Noel C, Abramowicz D, Durand D et al. Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol 2009: 20: 1385.
34. Abecassis M. Organ acquisition cost centers Part I: medicare regulations-truth or consequence. Am J Transplant 2006: 6: 2830.
35. Khan S, Tighiouart H, Kalra A, Raman G, Rohrer RJ, Pereira BJ. Resource utilization among kidney transplant recipients. Kidney Int 2003: 64: 657.
36. Ciancio G, Burke GW, Gaynor JJ et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 2005: 80: 457.
37. Issa NC, Fishman JA. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis 2009: 48: 772.